The HSE Drugs Group has recommended a treatment for Friedreich's Ataxia should not be funded by the State. The recommendation will go before a meeting of senior HSE management later this month for a final decision. Advocacy group Care Champions is among those to respond to the news, describing the decision as ‘disgraceful’. The Rare Diseases Technology Review Group supported bringing this drug to Ireland, and both the EMA and FDA have already approved it. The group also noted this decision is being made with the spotlight very much on Ireland“With Ireland's EU Presidency prioritizing rare diseases, this decision is being watched by the world.